June 30 (Reuters) - Celcuity Inc CELC.O:
CELCUITY REPORTS CLINICAL DATA FROM TWO EARLY PHASE STUDIES OF GEDATOLISIB
CELCUITY INC - PHASE 1 TRIAL SHOWS 66% SIX-MONTH RPFS RATE IN MCRPC
CELCUITY INC - PHASE 2 TRIAL SHOWS 43% ORR IN HER2+ MBC
Source text: ID:nGNX5WrxXV
Further company coverage: CELC.O
(((( Reuters.briefs@thomsonreuters.com ;));))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.